Weight-related quality of life, health utility, psychological well-being, and satisfaction with exenatide once weekly compared with sitagliptin or pioglitazone after 26 weeks of treatment.
about
Emerging utility of once-weekly exenatide in patients with type 2 diabetesExenatide once weekly: opportunities in the primary care setting.Comparison of GLP-1 analogues versus sitagliptin in the management of type 2 diabetes: systematic review and meta-analysis of head-to-head studies.Application of a health-related quality of life conceptual model in community-dwelling older Chinese people with diabetes to understand the relationships among clinical and psychological outcomes.GLP-1 receptor agonists vs. DPP-4 inhibitors for type 2 diabetes: is one approach more successful or preferable than the other?Efficacy and safety of switching from the DPP-4 inhibitor sitagliptin to the human GLP-1 analog liraglutide after 52 weeks in metformin-treated patients with type 2 diabetes: a randomized, open-label trial.Development and validation of the self-management profile for type 2 diabetes (SMP-T2D).Exenatide extended-release; clinical trials, patient preference, and economic considerations.Facilitating healthy coping in patients with diabetes: a systematic review.Dipeptidyl peptidase-4 inhibitors in type 2 diabetes therapy--focus on alogliptin.Patient-reported outcomes among patients using exenatide twice daily or insulin in clinical practice in six European countries: the CHOICE prospective observational study.Incorporating incretin-based therapies into clinical practice for patients with type 2 diabetes.Patient-reported outcomes in trials of incretin-based therapies in patients with type 2 diabetes mellitus.Red carpeting the newer antidiabetics.Exenatide extended-release: a review of its use in type 2 diabetes mellitus.Incretin-based therapies for type 2 diabetes mellitus: a review of direct comparisons of efficacy, safety and patient satisfaction.The place of GLP-1-based therapy in diabetes management: differences between DPP-4 inhibitors and GLP-1 receptor agonists.Sitagliptin: a review of its use in patients with type 2 diabetes mellitus.Efficacy, safety, and tolerability of exenatide once weekly in patients with type 2 diabetes mellitus: an integrated analysis of the DURATION trials.Exenatide Extended-Release: An Updated Review of Its Use in Type 2 Diabetes Mellitus.A Review of the Long-Term Efficacy, Tolerability, and Safety of Exenatide Once Weekly for Type 2 Diabetes.Practical Considerations for the Use of Subcutaneous Treatment in the Management of Dyslipidaemia.A patient-centred approach to treatment with incretin-based agents in patients with type 2 diabetes.An Indirect Comparison of Changes in the Impact of Weight on Quality of Life Among Subjects with Type 2 Diabetes Treated with Antihyperglycemic Agents in Dual Therapy with Metformin.Health-related quality of life (EQ-5D) among type 2 diabetes mellitus patients treated with dapagliflozin over 2 years.Exenatide improves excessive daytime sleepiness and wakefulness in obese patients with type 2 diabetes without obstructive sleep apnoea.Dipeptidyl peptidase-4 inhibitors as preferable oral hypoglycemic agents in terms of treatment satisfaction: Results from a multicenter, 12-week, open label, randomized controlled study in Japan (PREFERENCE 4 study).
P2860
Q26777320-25EA0EC0-8DE6-4BD8-AE7D-346158474586Q30431639-6432DF01-8E3C-497F-A48C-CC1AFAD3CFE7Q33999894-F9079071-BC80-4BFA-BC38-DCD2A617E299Q34523704-348DF4C0-8C84-4EF0-905D-2B88F2ACDC89Q34547492-33BD5A2D-01FB-4EDB-A5BC-339FCEFA0300Q36249636-463260B7-5312-45D3-B211-882C19DD6C18Q36521162-3F618952-2A8E-4C95-81FC-BE378308ED19Q36538817-574BEEAE-099D-418D-8A25-25D4E255C911Q36545261-937F7B6E-F0A3-428A-811A-85FB844E123FQ37195882-90BC4317-707F-48D6-8292-6686CC595110Q37509903-D7EC1136-66E5-4A88-B8DA-3585E211DC45Q37653125-3CA17FB6-DBDB-4235-8720-A068C3A669A8Q37993945-9B49EBD8-2F86-411E-8DFE-3C17DC3F846BQ38013105-CC90D1B2-DC16-4D43-BE4C-97D9FAFB6525Q38032321-6700B07E-D966-41B6-8BE0-E263AD370733Q38069507-58616FD3-DA69-4BB2-8CF1-2EE0C8453E1BQ38088195-79097766-EC81-492C-B80B-B048416D1074Q38177173-41DAE379-6D9A-4A41-B058-FBC7145EDEC7Q38450276-DB935A9E-092C-42BE-BEE5-9FD3014A0361Q38526870-3C19B22C-6834-487C-BD4F-044B97D20069Q38694894-DEB753A4-5F51-4925-A667-53EB035E1AC2Q39440767-6E6EBED3-ABFF-41A5-AF68-A49F805CCED9Q44310507-9427124A-EAF2-4024-A3A8-F066C90D1BEAQ47174001-1BF4A864-44BF-4EAD-9D72-DDBC7A2779F5Q48086602-B1EDE274-88AE-4C2C-92B9-A9D228D6DF69Q48237499-C7C92838-5C92-4838-8323-3AC937EB970EQ49180890-58022E45-2B6C-4DB1-8482-A4048D73FB68
P2860
Weight-related quality of life, health utility, psychological well-being, and satisfaction with exenatide once weekly compared with sitagliptin or pioglitazone after 26 weeks of treatment.
description
2011 nî lūn-bûn
@nan
2011 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
name
Weight-related quality of life ...... e after 26 weeks of treatment.
@ast
Weight-related quality of life ...... e after 26 weeks of treatment.
@en
Weight-related quality of life ...... e after 26 weeks of treatment.
@nl
type
label
Weight-related quality of life ...... e after 26 weeks of treatment.
@ast
Weight-related quality of life ...... e after 26 weeks of treatment.
@en
Weight-related quality of life ...... e after 26 weeks of treatment.
@nl
prefLabel
Weight-related quality of life ...... e after 26 weeks of treatment.
@ast
Weight-related quality of life ...... e after 26 weeks of treatment.
@en
Weight-related quality of life ...... e after 26 weeks of treatment.
@nl
P2093
P2860
P356
P1433
P1476
Weight-related quality of life ...... e after 26 weeks of treatment.
@en
P2093
Jaret Malloy
Jennie H Best
Louis P Garrison
Mark Peyrot
Richard R Rubin
P2860
P304
P356
10.2337/DC10-1119
P407
P577
2011-02-01T00:00:00Z